Literature DB >> 15831931

Biologics in inflammatory disease: infliximab associated risk of lymphoma development.

C Bucher, L Degen, S Dirnhofer, M Pless, R Herrmann, P Schraml, P Went.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15831931      PMCID： PMC1774485     

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  9 in total

1.  Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.

Authors:  S Lori Brown; Mark H Greene; Sharon K Gershon; Evelyne T Edwards; M Miles Braun
Journal:  Arthritis Rheum       Date:  2002-12

2.  Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab.

Authors:  E Roddy; P A Courtney; A Morris
Journal:  Rheumatology (Oxford)       Date:  2002-10       Impact factor: 7.580

3.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

Authors:  P Rutgeerts; G D'Haens; S Targan; E Vasiliauskas; S B Hanauer; D H Present; L Mayer; R A Van Hogezand; T Braakman; K L DeWoody; T F Schaible; S J Van Deventer
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

Review 4.  The relationship between infliximab treatment and lymphoma in Crohn's disease.

Authors:  S J Bickston; G R Lichtenstein; K O Arseneau; R B Cohen; F Cominelli
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

5.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

6.  Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.

Authors:  T Ljung; P Karlén; D Schmidt; P M Hellström; A Lapidus; I Janczewska; U Sjöqvist; R Löfberg
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

Review 7.  CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab.

Authors:  E Mahé; V Descamps; M Grossin; S Fraitag; B Crickx
Journal:  Br J Dermatol       Date:  2003-07       Impact factor: 9.302

8.  Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.

Authors:  Frederick Wolfe; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2004-06

9.  The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.

Authors:  Jean-Frederic Colombel; Edward V Loftus; William J Tremaine; Laurence J Egan; W Scott Harmsen; Cathy D Schleck; Alan R Zinsmeister; William J Sandborn
Journal:  Gastroenterology       Date:  2004-01       Impact factor: 22.682
  9 in total
  3 in total

1.  The role of mucosal healing in the treatment of patients with inflammatory bowel disease.

Authors:  Byron P Vaughn; Sveta Shah; Adam S Cheifetz
Journal:  Curr Treat Options Gastroenterol       Date:  2014-03

2.  Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system.

Authors:  Hélène Théophile; Thierry Schaeverbeke; Ghada Miremont-Salamé; Abdelilah Abouelfath; Valentine Kahn; Françoise Haramburu; Bernard Bégaud
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

3.  Novel treatment options for ulcerative colitis.

Authors:  Byron P Vaughn; Alan C Moss
Journal:  Clin Investig (Lond)       Date:  2013-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.